SLAMF7 and plasma cell myeloma: A bi-specific Ab-recognizing CS1-NKG2D, which comprises an anti-NKG2D scFv and an anti-CS1 scFv, showed enhanced cytotoxicity and cytokine production from NK cells and significantly prolonged their survival in a multiple myeloma xenograft NOD-SCIDIL2γc−/− (NSG) mouse model (104).